| [1] |
Zairi F, Marinho P, Bouras A, et al. Recent concepts in the management of thoracolumbar spine metastasis[J]. J Neurosurg Sci. 2013, 57(1): 45-54.
|
| [2] |
贾连顺，陈江华. 脊柱转移瘤外科诊断治疗的现状与进展[J]. 中华骨科杂志，2003, 23(6): 331-334.
|
| [3] |
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007[J]. CA Cancer J Clin, 2007, 57(1): 43-66.
|
| [4] |
Lutz S, Lo SS, Chow E, et al. Radiotherapy for metastatic bone disease: current standards and future prospectus[J]. Expert Rev Anticancer Ther, 2010, 10(5): 683-695.
|
| [5] |
Chow E, Zeng L, Salvo N, et al. Update on the systematic review of palliative radiotherapy trials for bone metastases[J]. Clin Oncol, 2012, 24(2): 112-124.
|
| [6] |
Yoon F, Morton GC. Single fraction radiotherapy versus multiple fraction radiotherapy for bone metastases in prostate cancer patients: comparative effectiveness[J]. Cancer Manag Res, 2014, 6: 451-457.
|
| [7] |
Rades D, Stalpers LJ, Veninga T, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression[J]. J Clin Oncol, 2005, 23(15): 3366-3375.
|
| [8] |
Harel R, Zach L. Spine radiosurgery for spinal metastases: indications, technique and outcome[J]. Neurol Res, 2014, 36(6): 550-556.
|
| [9] |
Lo SS, Sahgal A, Wang JZ, et al. Stereotactic body radiation therapy for spinal metastases[J]. Discov Med, 2010, 9(47): 289-296.
|
| [10] |
Chawla S, Schell MC, Milano MT. Stereotactic body radiation for the spine: a review[J]. Am J Clin Oncol, 2013, 36(6): 630-636.
|
| [11] |
Bate BG, Khan NR, Kimball BY, et al. Stereotactic radiosurgery for spinal metastases with or without separation surgery[J]. J Neurosurg Spine, 2015, 22(4): 409-415.
|
| [12] |
Cunha MV, Al-Omair A, Atenafu EG, et al. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy(SBRT): analysis of predictive factors[J]. Int J Radiat Oncol Biol Phys, 2012, 84(3): 343-349.
|
| [13] |
Thibault I, Al-Omair A, Masucci GL, et al. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture[J]. J Neurosurg Spine, 2014, 21(5): 711-718.
|
| [14] |
Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review[J]. J Clin Oncol, 2007, 25(11): 1423-1436.
|
| [15] |
Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer[J]. Eur Urol, 2013, 63(2): 189-197.
|
| [16] |
雷明星，刘蜀彬，郑文静，等. 脊柱转移瘤外科治疗原则[J/CD]. 中华损伤与修复杂志(电子版), 2017, 12(3): 207-211.
|
| [17] |
Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial[J]. Lancet, 2005, 366(9486): 643-648.
|
| [18] |
Lee CH, Kwon JW, Lee J, et al. Direct decompressive surgery followed by radiotherapy versus radiotherapy alone for metastatic epidural spinal cord compression: a meta-analysis[J]. Spine, 2014, 39(9): E587-E592.
|
| [19] |
Crnalic S, Hildingsson C, Wikström P, et al. Outcome after surgery for metastatic spinal cord compression in 54 patients with prostate cancer[J]. Acta Orthop, 2012, 83(1): 80-86.
|
| [20] |
Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial[J]. Lancet Oncol, 2011, 12(3): 225-235.
|
| [21] |
Coxon FP, Rogers MJ. The role of prenylated small GTP-binding proteins in the regulation of osteoclast function[J]. Calcif Tissue Int, 2003, 72(1): 80-84.
|
| [22] |
Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group[J]. J Clin Oncol, 2003, 21(16): 3150-3157.
|
| [23] |
Winquist E, Berry S. Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma[J]. J Natl Cancer Inst, 2004, 96(15): 1183.
|
| [24] |
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma[J]. J Natl Cancer Inst, 2002, 94(19): 1458-1468.
|
| [25] |
Wirth M, Tammela T, Cicalese V, et al. Prevention of bone metastases in patients with high-risk non metastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)[J]. Eur Urol, 2015, 67(3): 482-491.
|
| [26] |
Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)[J]. J Clin Oncol, 2014, 32(11): 1143-1150.
|
| [27] |
Brown JE, Coleman RE. Denosumab in patients with cancer-a surgical strike against the osteoclast[J]. Nat Rev Clin Oncol, 2012, 9(2): 110-118.
|
| [28] |
Dougall WC, Holen I, González Suárez E. Targeting RANKL in metastasis[J]. Bonekey Rep, 2014, 3: 519.
|
| [29] |
Lipton A, Fizazi K, Stopeck AT, et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics[J]. Eur J Cancer, 2016, 53: 75-83.
|
| [30] |
Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study[J]. Lancet. 2011, 377(9768): 813-822.
|
| [31] |
Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial[J]. Lancet, 2012, 379(9810): 39-46.
|
| [32] |
Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with non metastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time[J]. J Clin Oncol, 2013, 31(30): 3800-3806.
|